Occlusion of the cerebral arteries in Recklinghausen's disease

Summary Two children, aged 18 months and 6 years, who had Recklinghausen's disease, had occlusion of cerebral arteries. One child had no motor deficit but the other had right hemiparesis and partial occlusion of the left posterior cerebral artery, a fact not found in the literature.     

超声观察肝癌多次肝动脉栓塞术治疗前后肝脏声像图的变化及其预后的评估

目的探讨超声在评估肝癌肝动脉栓塞术后肝硬变受损程度方面的价值.方法对43例原发性肝癌患者进行了肝动脉栓塞术前与术后临床肝功能检查及超声分析.结果多次肝动脉栓塞术后肝硬变程度加重,根据Child‘s分级肝功能下降率达67.4%,超声检查肝硬变加重率达70%.两者检查结果相一致.结论超声观察肝内回声的变化对评估多次肝癌肝动脉栓塞术后肝功能损害程度有重要作用.     

甲状腺动脉栓塞治疗难治性甲状腺机能亢进

目的 探讨经导管甲状腺动脉栓塞治疗难治性甲状腺机能亢进的方法及疗效。方法 使用高压消毒后明胶海绵、聚乙烯醇(PVA)微球栓塞甲状腺上动脉及下动脉。结果 13例病人甲状腺动脉栓塞成功，颈围缩小，11例T3、T4降至正常，2例轻废增高。结论 经导管甲状腺动脉栓塞治疗难治性甲状腺机能亢进可作为内外科治疗及^131I治疗替代疗法，只要正确掌握操作方法，是安全有效的。     

动脉化疗在中晚期膀胱癌治疗中应用的初步报告

自1996年1月至今，我科为12例晚期膀胱癌患者施行了髂内动脉灌注化疗。结果：1例T4期降至T2期后给予膀胱部分切除；7例经手术＋动脉化疗，2年复查未发现复发现象；4例带瘤生存，病灶无进展。动脉化疗毒性反应较轻，疗效是肯定的，为中晚期膀胱癌开辟了一条新的治疗途径。     

肢体动脉阻塞性疾病的介入溶栓治疗

目的探讨栓子内溶栓治疗肢体动脉急、慢性阻塞性疾病的方法和效果。方法12例血管造影证实为肢体动脉阻塞者,将导管和溶栓导丝插入血栓内,以4000U/min尿激酶(UK)灌注直至血栓溶解。结果病程<3d者6例,血管全部再通,UK平均用量67万U;病程>2个月者6例,血管再通5例,UK平均用量106万U,1例无效者病程4.2年。术中术后无严重并发症。结论栓子内溶栓安全有效,是治疗肢体动脉急、慢性阻塞性疾病的优先选择的方法。     

选择性动脉灌注化疗联合靶向药物治疗非小细胞肺癌多发脑转移

背景与目的 本研究旨在回顾性分析选择性动脉灌注化疗联合赖氨酸激酶抑制剂( tyrosine kinase inhibitor,TKI)药物治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)多发脑转移的临床疗效及预后相关因素.方法 自2008年9月-2011年10月共入组31例诊断明确的非小细胞肺癌经CT或MRI证实多发脑转移瘤(＞3个)的患者,行选择性颅内动脉、支气管动脉及相关靶动脉化疗药物灌注化疗2个-6个周期,每周期间隔4周,同步或后续联合厄洛替尼、吉非替尼或埃克替尼治疗.介入治疗2个周期或联合靶向治疗后每4周应用CT和MRI对肿瘤进行疗效评价,直至肿瘤进展或发生不可耐受性化疗药物不良反应.结果 31例患者平均行3个周期介入治疗,随访时间4个-40.9个月,完全缓解5例(16.1％),部分缓解7例(22.6％),疾病稳定11例(35.5％),疾病进展8例(25.8％).客观缓解率( objective response rate,ORR)为38.7％,疾病控制率(disease control rate,DCR)为74.2％.中位无进展生存期(progression free survival,PFS)为13.1个月,中位总生存期(overall survival,OS)为15.1个月.6个月的生存率为79％,1年生存率为61.1％,2年生存率为31.1％.分层分析显示PFS、OS与吸烟状态、病理类型、颅外转移情况、靶向药物应用时间、PS评分具有相关性;与性别、年龄、既往治疗情况、脑转移数目无明显相关.结论 选择性动脉灌注化疗联合靶向药物是治疗非小细胞肺癌多发脑转移安全有效的方法之一,吸烟状态、PS评分、肿瘤病理类型、颅外转移状况、靶向药物应用时间均可影响患者预后.     

Arterial infusion therapy with low-dose cisplatin and continuous 5-fluorouracil for isolated hepatic recurrence of gastric carcinoma

Patients with metachronous liver metastasis after curative resection of gastric carcinoma generally have a poor prognosis, even when recurrence is confined to the liver. We report a patient in whom hepatic arterial infusion therapy with bolus low-dose cisplatin (CDDP) and continuous 5-fluorouracil (5-FU) was effective against large metastases confined to the liver. An 83-year-old man was admitted with huge liver metastases from gastric carcinoma. Intra-arterial bolus injection of low-dose CDDP (5 mg) and continuous intra-arterial infusion of 5-FU (250 mg/day for 7 days) was started. After four courses of this arterial infusion therapy, computed tomography scans revealed shrinkage of the liver metastases. He was followed-up as an outpatient and continued to receive the arterial infusion therapy once every 4 weeks. Throughout the course of the chemotherapy, a partial response of the liver metastases was maintained. The patient had an improved quality of life after starting the chemotherapy, and he survived for 16 months from the commencement of the therapy. Arterial infusion therapy with bolus low-dose CDDP and continuous 5-FU may be recommended for patients with isolated hepatic recurrence of gastric carcinoma. Received: September 6, 1999 / Accepted: January 31, 2000     

糖尿病下肢动脉病变的彩色多普勒诊断及其危险因素分析

目的 探讨彩色多普勒对糖尿病下肢动脉病变（ＬＥＡＤＤＰ）的诊断价值及有关ＬＥＡＤＤＰ的危险因素。方法 应用彩色多普勒检测了５０例糖尿病病人的双侧下肢动脉,同时与３０例正常人对照;应用多因素逐步回归分析方法对有关ＬＥＡＤＤＰ的危险因素作了探讨。结果 本组发现ＬＥＡＤＤＰ２１例,占４２％。多因素分析显示对ＬＥＡＤＤＰ影响最大的前二个因素依次是：空腹血糖水平升高及高密度脂蛋白－胆固醇水平降低。与糖尿病并